SEC 13F Intelligence

Managers / Q1 2026

Sarissa Capital Management LP

CIK 0001577524 · 500 WEST PUTNAM AVENUE, SUITE 400, GREENWICH, CT, 06830 · 203-302-2330

Reported Value
$158M
Q1 2026
Positions
9
Filings on Record
30
2019–present window
Filed
May 15, 2026
original filing

Summary

Sarissa Capital Management LP reported $158M in U.S.-listed holdings across 9 positions for Q1 2026.

The portfolio is heavily concentrated: INVA alone accounts for 31.5% of reported value.

The book was largely unchanged from Q4 2025.

Portfolio Metrics

Turnover
+0.8%
vs prior filed quarter
Largest Position
+31.5%
Innoviva

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $451MQ4 ’18Q1 ’19: $664MQ2 ’19: $802MQ3 ’19: $798MQ4 ’19: $1.2BQ4 ’19Q1 ’20: $784MQ2 ’20: $899MQ3 ’20: $849MQ4 ’20: $980MQ4 ’20Q1 ’21: $1.0BQ2 ’21: $1.3BQ3 ’21: $1.3BQ4 ’21: $1.2BQ4 ’21Q1 ’22: $1.1BQ2 ’22: $993MQ3 ’22: $885MQ4 ’22: $840MQ4 ’22Q1 ’23: $782MQ2 ’23: $1.0BQ3 ’23: $742MQ4 ’23: $649MQ4 ’23Q1 ’24: $572MQ2 ’24: $592MQ3 ’24: $402MQ4 ’24: $323MQ4 ’24Q1 ’25: $155MQ2 ’25: $154MQ3 ’25: $180MQ4 ’25: $223MQ4 ’25Q1 ’26: $158Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 81.6%ADR: 15.4%Other: 3.0%
  • Common Stock · 81.6% · $129M
  • ADR · 15.4% · $24M
  • Other · 3.0% · $5M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
NBIXNEUROCRINE BIOSCIENCES INCTRIMMED−186.6K116.5K−$28M$15M
CYTKCYTOKINETICS INCTRIMMED−167.7K228.6K−$10M$15M
IRWDIRONWOOD PHARMACEUTICALS INCTRIMMED−6.73M9.19M−$21M$32M
INVAINNOVIVA INCTRIMMED−685.1K2.13M−$7M$50M
BIOHAVEN LTDADDED+50.0K563.2K−$1M$5M
LNTHLANTHEUS HLDGS INCTRIMMED−14.5K166.9K+$585,308$13M
EH3AMARIN CORP PLCHELD+01.67M+$845,065$24M
VORVOR BIOPHARMA INCHELD+025.4K+$120,899$453,118

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2026

9 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1INVAINNOVIVA INChistory →COM31.50%$50M2.13M
2IRWDIRONWOOD PHARMACEUTICALS INChistory →COM CL A20.46%$32M9.19M
3EH3AMARIN CORP PLChistory →SPONSORED ADR15.35%$24M1.67M
4NBIXNEUROCRINE BIOSCIENCES INChistory →COM9.74%$15M116.5K
5CYTKCYTOKINETICS INChistory →COM NEW9.56%$15M228.6K
6LNTHLANTHEUS HLDGS INChistory →COM8.03%$13M166.9K
7BIOHAVEN LTDCOM3.02%$5M563.2K
8REGNREGENERON PHARMACEUTICALShistory →COM2.05%$3M4.2K
9VORVOR BIOPHARMA INCCOM NEW0.29%$453,11825.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$158M9May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$223M9Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$180M8Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$154M7Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$155M7May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$323M8Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$402M10Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$592M10Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$572M10May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$649M9Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$742M11Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$1.0B11Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$782M11May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$840M11Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$885M11Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$993M11Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.1B11May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$1.2B11Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.3B10Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.3B14Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.0B14May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$980M12Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$849M11Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$899M12Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$784M12May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.2B13Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$798M12Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$802M13Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$664M11May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$451M10Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.